At a glance
| Our verdict | Lowers blood sugar a little (about 0.4%), never tested on heart or kidney outcomes, and blocks the enzymes that clear many medicines. |
| Sold for | Blood sugar, weight and cholesterol (claimed) |
| How sure the evidence is | Low to Very low |
| Cost a month | About $20 to $34 |
Written for adults in Canada. It explains the evidence; it is not advice for you personally. Last reviewed 20 October 2026.
Supplement Check
Is it right for you?
Already taking berberine? It changes the levels of many common medicines. Your check tells you whether to stop it, and what would work better. Our Supplement Check looks at:
- Pregnancy and breastfeeding: do not take it (newborn jaundice)
- Anyone taking a medicine in the table above
- Kidney or organ transplant
- Cancer, especially on tamoxifen or an oral cancer medicine
- G6PD deficiency
- Every medicine you take
Coming soon. The Supplement Check and the Online Health Assessment open once our safety testing is complete.
$59 when it opens, paid once. Adults 18 and over, anywhere in Canada. While the service is new, Dr. French reads every report himself, and your report arrives within 3 working days. More about the Supplement Check
What it is
Berberine is a plant alkaloid from Coptis (huang lian), Phellodendron, barberry, goldenseal and Oregon grape. Most trials used berberine hydrochloride. Shelf products also include whole-herb extracts (goldenseal, Coptis), whose berberine content varies, and “dihydroberberine” or “phytosome” forms marketed as better absorbed, which have no glucose trials. Less than 1% of a dose of berberine hydrochloride is absorbed.
How it acts
Mostly in the gut and liver. It switches on an energy-sensing enzyme (AMP-activated protein kinase) in a way that resembles metformin, increases insulin receptors, reduces glucose absorption from the gut, and changes gut bacteria and bile acids. It lowers LDL cholesterol a little by keeping more LDL receptors on liver cells. [1, 2]
What it is used for, and what the evidence says
| Use | What the trials found | How sure we are |
|---|---|---|
| Type 2 diabetes, average blood sugar (HbA1c) | Pooled reviews of 27 to 50 trials report HbA1c 0.5 to 0.7% lower. [3, 4] But almost all were done in China, many published in Chinese-language journals, most lasted 8 to 12 weeks, and many were open-label. An audit of “randomised” trials in Chinese journals found only 6.8% were truly randomised. [5] The effect shrinks to nothing in trials longer than 90 days and in people over 60, a pattern that points to small-study bias. The best-run placebo-controlled trial (409 people, 20 centres) found 0.4% more than placebo. [2] A pharmaceutical berberine salt (not sold as a supplement) gave 0.4 to 0.7%. [6] Our best estimate: about −0.4%, possibly zero. | Low |
| Prediabetes | No adequately sized trial. No trial has measured whether it prevents diabetes. | Very low |
| Head to head with metformin | Small trials (about 18 people per group) reported “similar” results. [7] None was designed to prove the two are equal; “no significant difference” in a trial that small is not equivalence. | Very low |
| Weight | Between 0 and 2 kg in pooled trials. [8, 9] The claim that it works like the weight-loss injections is false: semaglutide 2.4 mg lowered body weight by 14.9% against 2.4% with placebo. [10] In a 2026 trial of 337 people taking 1 g a day for 6 months, berberine did not reduce belly fat or liver fat. [11] | Very low |
| LDL cholesterol | Berberine alone: about 0.24 mmol/L lower, and the range includes zero. [12] A statin lowers LDL by 30 to 50%. | Very low to Low |
| Heart attack, stroke, kidney failure, death | No trial of berberine has measured any of them. | No evidence |
How sure we are: High means further research is very unlikely to change the answer; Moderate, it might; Low, it may well change; Very low, we are very unsure. These follow the GRADE method that guideline panels use.
Benefits
- Average blood sugar (HbA1c), type 2 diabetes: About −0.4% (0 to −0.7); Low
- Fasting blood sugar, type 2 diabetes: About −0.5 mmol/L; Low
- Prediabetes: Unknown; Very low
- Body weight: 0 to −2 kg; Very low
- LDL cholesterol: About −0.24 mmol/L, may be zero; Very low to Low
- Triglycerides: About −0.2 mmol/L; Low
- Heart, kidney, death: Not studied; No evidence
Risks and side effects
- Gut upset: constipation, diarrhoea, cramps, bloating, nausea. About a third of people in one trial. [7]
- Low blood sugar when added to insulin or a sulfonylurea (gliclazide, glyburide, glimepiride).
- Jaundice in newborns. Berberine pushes bilirubin off its carrier protein far more strongly than some medicines known to do this; [13] herbs containing it were banned in Singapore for about 30 years after newborn jaundice and brain injury in babies with G6PD deficiency. [14]
- Unreliable products. About 45% of berberine and goldenseal products tested in 2023 had a problem: under-filled, lead contamination, or almost no berberine.
Interactions with medicines
This is the main reason we do not recommend it. Measured in people, not just in the test tube: two weeks of berberine at a lower dose than the 1,500 mg a day usually sold strongly blocked CYP2D6 (ninefold), and also blocked CYP2C9 and CYP3A4, three of the liver enzymes that clear most medicines. [15] In 52 kidney-transplant patients, berberine raised ciclosporin levels by 29% or more. [16]
| Medicine | What can happen | What to do |
|---|---|---|
| Ciclosporin, tacrolimus, sirolimus | Higher levels, toxicity | Do not take; doctor told the same day |
| Tamoxifen | Less of the active drug; lower cancer protection | Do not take; doctor told the same day |
| Warfarin, phenytoin, celecoxib | Higher levels; bleeding with warfarin | Do not take; same day for warfarin |
| Simvastatin, lovastatin, atorvastatin | Higher statin levels, muscle damage | Do not take |
| Codeine, tramadol | Less pain relief | Do not take |
| Metoprolol, carvedilol, propafenone, flecainide | Higher levels, slow heart rate | Do not take |
| Paroxetine, fluoxetine, venlafaxine, tricyclics, atomoxetine, aripiprazole, risperidone | Higher levels | Do not take |
| Insulin, gliclazide, glyburide, glimepiride | Low blood sugar | Do not take; same day |
| Midazolam, triazolam, quetiapine, calcium-channel blockers, apixaban, rivaroxaban, ticagrelor, many oral cancer medicines | Higher levels | Do not take |
| Metformin, SGLT2 inhibitors, GLP-1 medicines | Added blood-sugar lowering; more gut upset with metformin | Discuss with your doctor |
| Digoxin, dabigatran | Possible change in levels (little human data) | Discuss with your doctor |
Who should not take it
- Pregnancy and breastfeeding: do not take it (newborn jaundice).
- Anyone taking a medicine in the table above.
- Kidney or organ transplant.
- Cancer, especially on tamoxifen or an oral cancer medicine.
- G6PD deficiency.
- Diabetes treated with insulin or a sulfonylurea.
- Severe kidney disease or cirrhosis of the liver (no data).
- Under 18.
- Older adults on several medicines: interactions are likely, and the effect was smaller over 60.
Dose and timing
We do not recommend a dose. For reference, trials used berberine hydrochloride 0.9 to 1.5 g a day, split into 2 or 3 doses with meals, for 1 to 3 months; higher doses did no better. Canadian labels say to discuss use beyond 3 months with a doctor.
If you take it now: the only way to know whether it works is an HbA1c test after 3 months. The expected change (about 0.4%) is barely more than the test's own variation (0.2 to 0.3%), so in one person it may be impossible to tell.
What we know about Canadians
Berberine is sold in Canada as a licensed natural health product with the claim “helps support healthy glucose metabolism”. That is a support claim, not a diabetes-treatment claim; some Canadian retail pages go further than the licence allows. Few Canadian brands publish batch heavy-metal results.
Interest in weight-loss medicines is high and largely self-funded: public drug plans spent $807 million on semaglutide in 2024, the single largest driver of growth in public drug spending, and most public plans still cover these medicines for diabetes only. [17] That gap is where berberine is sold as a natural alternative. Nearly half of Canadians (45.6%) took a supplement in 2015. [18]
How sure are we: not graded. No Canadian data on berberine use or on diabetes in this review; the text is from the licence wording and Canadian supplement-use and GLP-1 spending data.
An honest comparison: blood sugar in type 2 diabetes
Same outcome (HbA1c, average blood sugar over 3 months), same units, cost a month in Canadian dollars before any drug plan.
| Option | Effect | How sure we are | Cost a month (CAD) |
|---|---|---|---|
| Soluble fibre, about 13 g a day | HbA1c −0.58% [21] | Moderate | $15 to $30 |
| Berberine 1,500 mg a day | HbA1c about −0.4% (0 to −0.7); weight 0 to −2 kg; no outcome data | Low | $20 to $34 |
| Structured exercise (aerobic and strength, over 150 minutes a week) | HbA1c −0.67%; −0.89% above 150 minutes a week [19] | Moderate to High | $0 (walking) to $40–80 (gym) |
| Weight loss (intensive programme) | 58% fewer new cases of diabetes in prediabetes; [20] 46% remission of diabetes at a year in one trial | High | $0 to $250 |
| Metformin (generic) | HbA1c −1.1%; [22] fewer heart attacks and deaths in overweight people with diabetes; [23] 31% fewer new cases of diabetes [20] | High | $8 to $15 |
| SGLT2 inhibitors (empagliflozin, dapagliflozin) | HbA1c −0.5 to −0.8%; heart-failure admissions −31%, kidney decline −45% [24] | High | $70 to $115 (generic dapagliflozin) |
| GLP-1 medicines (semaglutide) | HbA1c −1.5 to −1.8%; weight −14.9% at the obesity dose; [10] fewer heart attacks and strokes | High | $220 to $260 |
Read honestly: berberine's best estimate is below soluble fibre, below structured exercise, about a third of metformin and a quarter of semaglutide, with no outcome data and the worst interaction profile on the list. Metformin costs less.
Why we don't recommend it
We do not sell berberine and our check never recommends it. It lowers blood sugar a little, the size of the effect is inflated by small, low-quality trials, it has never been shown to prevent heart disease, kidney disease or diabetes complications, and it changes the blood levels of many common medicines.
Already taking it? Discuss it with your doctor. Stop it now if you are pregnant, planning a pregnancy or breastfeeding, or if you take a medicine in the interaction table. If your blood sugar is rising, ask your doctor about metformin: it lowers HbA1c about three times as much, costs less, and has decades of safety data.
Dr. French reviewed berberine against metformin, the SGLT2 inhibitors and the GLP-1 medicines and was not convinced. Its best-estimate effect is small and inflated by small, low-quality trials; it has no heart, kidney or survival data; and in people it blocks three of the liver enzymes that clear most medicines. A generic medicine that does more, with decades of outcome data, costs less. So we do not sell it, and if you already take it, discuss it with your doctor.
Supplement Check
Before you buy it, get it checked
Already taking berberine? It changes the levels of many common medicines. Your check tells you whether to stop it, and what would work better. Our Supplement Check looks at:
- Pregnancy and breastfeeding: do not take it (newborn jaundice)
- Anyone taking a medicine in the table above
- Kidney or organ transplant
- Cancer, especially on tamoxifen or an oral cancer medicine
- G6PD deficiency
- Every medicine you take
Coming soon. The Supplement Check and the Online Health Assessment open once our safety testing is complete.
$59 when it opens, paid once. Adults 18 and over, anywhere in Canada. While the service is new, Dr. French reads every report himself, and your report arrives within 3 working days. More about the Supplement Check
Disclosure of financial interest
White Pine Medical earns money from products bought through our Fullscript dispensary. Dr. French's Code of Ethics requires him to tell you this. You do not have to buy anything from us: every product is named by its ingredient and dose so you can buy it at any pharmacy, and the advice is the same wherever you buy it, or if you buy nothing.
References
- Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344-51.
- Zhang Y, Gu Y, Ren H, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nat Commun. 2020;11(1):5015.
- Xie W, Su F, Wang G, et al. Glucose-lowering effect of berberine on type 2 diabetes: a systematic review and meta-analysis. Front Pharmacol. 2022;13:1015045.
- Liang Y, Xu X, Yin M, et al. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocr J. 2019;66(1):51-63.
- Wu T, Li Y, Bian Z, Liu G, Moher D. Randomized trials published in some Chinese journals: how many are randomized? Trials. 2009;10:46.
- Ji L, Ma J, Ma Y, et al. Berberine ursodeoxycholate for the treatment of type 2 diabetes: a randomized clinical trial. JAMA Netw Open. 2025;8(3):e2462185.
- Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-7.
- Asbaghi O, Ghanbari N, Shekari M, et al. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr ESPEN. 2020;38:43-9.
- Xiong P, Niu L, Talaei S, et al. The effect of berberine supplementation on obesity indices: a dose-response meta-analysis and systematic review of randomized controlled trials. Complement Ther Clin Pract. 2020;39:101113.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
- Lei et al. Berberine 1 g a day for 6 months in 337 people. JAMA Netw Open. 2026. (Full citation in the 20 Oct follow-up review.)
- Hernandez AV, Hwang J, Nasreen I, et al. Impact of berberine or berberine combination products on lipoprotein, triglyceride and biological safety marker concentrations in patients with hyperlipidemia: a systematic review and meta-analysis. J Diet Suppl. 2023.
- Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993;63(4):201-8.
- Linn YC, Lu J, Lim LC, et al. Berberine-induced haemolysis revisited: safety of Rhizoma coptidis and Cortex phellodendri in chronic haematological diseases. Phytother Res. 2012;26(5):682-6.
- Guo Y, Chen Y, Tan ZR, Klaassen CD, Zhou HH. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-7.
- Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567-72.
- Canadian Institute for Health Information data, reported in Healthcare Quarterly, 2026.
- Statistics Canada. Canadian Community Health Survey – Nutrition, 2015: supplement use.
- Umpierre D, Ribeiro PA, Kramer CK, et al. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2011;305(17):1790-9.
- Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
- Jovanovski E, Khayyat R, Zurbau A, et al. Should viscous fiber supplements be considered in diabetes control? Results from a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2019;42(5):755-66.
- Hirst JA, Farmer AJ, Ali R, et al. Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care. 2012;35(2):446-54.
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-65.
- Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31-9.
Costs marked as estimates are typical Canadian retail or pharmacy prices, before any drug plan. Certainty grades are ours unless the review gave its own.